These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Comparative evaluation of stable TAFIa variants: importance of alpha-helix 9 and beta-sheet 11 for TAFIa (in)stability. Ceresa E, De Maeyer M, Jonckheer A, Peeters M, Engelborghs Y, Declerck PJ, Gils A. J Thromb Haemost; 2007 Oct; 5(10):2105-12. PubMed ID: 17666015 [Abstract] [Full Text] [Related]
10. Activation of protein C and thrombin activable fibrinolysis inhibitor on cultured human endothelial cells. Wu C, Kim PY, Swystun LL, Liaw PC, Weitz JI. J Thromb Haemost; 2016 Feb; 14(2):366-74. PubMed ID: 26663133 [Abstract] [Full Text] [Related]
11. Selective modulation of thrombin-activatable fibrinolysis inhibitor (TAFI) activation by thrombin or the thrombin-thrombomodulin complex using TAFI-derived peptides. Plug T, Marquart JA, Marx PF, Meijers JC. J Thromb Haemost; 2015 Nov; 13(11):2093-101. PubMed ID: 26341360 [Abstract] [Full Text] [Related]
13. Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity. Zhou X, Weeks SD, Ameloot P, Callewaert N, Strelkov SV, Declerck PJ. J Thromb Haemost; 2016 Aug; 14(8):1629-38. PubMed ID: 27279497 [Abstract] [Full Text] [Related]
14. VhH anti-thrombomodulin clone 1 inhibits TAFI activation and enhances fibrinolysis in human whole blood under flow. van Moorsel MVA, Poolen GC, Koekman CA, Verhoef S, de Maat S, Barendrecht A, van Kleef ND, Meijers JCM, Schiffelers RM, Maas C, Urbanus RT. J Thromb Haemost; 2022 May; 20(5):1213-1222. PubMed ID: 35170225 [Abstract] [Full Text] [Related]
15. Elements of the primary structure of thrombomodulin required for efficient thrombin-activable fibrinolysis inhibitor activation. Wang W, Nagashima M, Schneider M, Morser J, Nesheim M. J Biol Chem; 2000 Jul 28; 275(30):22942-7. PubMed ID: 10801821 [Abstract] [Full Text] [Related]
16. Generation of a stable activated thrombin activable fibrinolysis inhibitor variant. Ceresa E, Van de Borne K, Peeters M, Lijnen HR, Declerck PJ, Gils A. J Biol Chem; 2006 Jun 09; 281(23):15878-83. PubMed ID: 16595693 [Abstract] [Full Text] [Related]
17. Role of isoleucine residues 182 and 183 in thrombin-activatable fibrinolysis inhibitor. Marx PF, Havik SR, Bouma BN, Meijers JC. J Thromb Haemost; 2005 Jun 09; 3(6):1293-300. PubMed ID: 15946220 [Abstract] [Full Text] [Related]
18. Generation of a stable thrombin-activatable fibrinolysis inhibitor deletion mutant exerting full carboxypeptidase activity without activation. Zhou X, Declerck PJ. J Thromb Haemost; 2015 Jun 09; 13(6):1084-9. PubMed ID: 25773535 [Abstract] [Full Text] [Related]
19. Generation and characterization of a highly stable form of activated thrombin-activable fibrinolysis inhibitor. Marx PF, Havik SR, Marquart JA, Bouma BN, Meijers JC. J Biol Chem; 2004 Feb 20; 279(8):6620-8. PubMed ID: 14660622 [Abstract] [Full Text] [Related]
20. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor. Bajzar L, Nesheim M, Morser J, Tracy PB. J Biol Chem; 1998 Jan 30; 273(5):2792-8. PubMed ID: 9446587 [Abstract] [Full Text] [Related] Page: [Next] [New Search]